This company seems to have been delisted
Reason: Acquired by Alfasigma
Last recorded trade on: January 10, 2024
Source: https://www.alfasigma.com/corporate/alfasigma-completes-acquisition-of-intercept-pharmaceuticals-inc/
Reason: Acquired by Alfasigma
Last recorded trade on: January 10, 2024
Source: https://www.alfasigma.com/corporate/alfasigma-completes-acquisition-of-intercept-pharmaceuticals-inc/
Intercept Pharmaceuticals
ICPT
₹1,629
Share price
0.00%
Change (1 day)
-5.46%
Change (1 year)
Categories
Intercept Pharmaceuticals (ICPT) Fails to deliver data
Key failure to deliver metrics for Intercept Pharmaceuticals :
- Last SEC data release: 2024-10-11
- Last 15 days FTD volume: N/A
- Last 3 months FTD volume: N/A
- Last year FTD volume: N/A
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for Intercept Pharmaceuticals (ICPT) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for Intercept Pharmaceuticals (ICPT) - since 2013
Volume in USD (price x number of shares), data since 2013Intercept Pharmaceuticals (ICPT) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2023 | ₹56.53 M | -5.59% |
| 2022 | ₹59.88 M | 37.34% |
| 2021 | ₹43.6 M | 15.32% |
| 2020 | ₹37.81 M | -76.1% |
| 2019 | ₹0.15 B | 54.79% |
| 2018 | ₹0.10 B | -51.34% |
| 2017 | ₹0.21 B | 11.01% |
| 2016 | ₹0.18 B | 25.1% |
| 2015 | ₹0.15 B | -30.01% |
| 2014 | ₹0.21 B | 3747.99% |
| 2013 | ₹5.61 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3 months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Eli Lilly LLY | ₹33.35 M | ₹0.20 B | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | ₹39.5 M | ₹0.27 B | 🇺🇸 USA |
 Gilead Sciences GILD | ₹0.16 B | ₹0.25 B | 🇺🇸 USA |
 MediciNova MNOV | ₹0 M | ₹0.08 M | 🇺🇸 USA |